Hematologic parameters after 8 weeks of treatment with pomalidomide and/or hydroxyurea in transgenic sickle cell mice
| Parameter . | WT (C57BL/6) . | Vehicle . | Pomalidomide . | Hydroxyurea HD . | Pomalidomide + hydroxyurea (C/HD) . | Pomalidomide + hydroxyurea (C/LD) . |
|---|---|---|---|---|---|---|
| Peripheral blood | ||||||
| RBCs, × 106/μL | 8.9 ± 0.1*† | 4.8 ± 0.1 | 5.5 ± 0.2‡ | 4.5 ± 0.5 | 4.3 ± 0.4*‡ | 5.5 ± 0.2‡ |
| Total Hb, g/dL | 13.7 ± 0.2*† | 7.2 ± 0.4 | 7.7 ± 0.3 | 6.1 ± 0.5 | 5.7 ± 0.5*‡§ | 7.7 ± 0.3 |
| Hct, % | 46.6 ± 1.58*† | 28.2 ± 1.1 | 28.9 ± 1.2 | 23.6 ± 3.0 | 23.9 ± 2.0 | 31.7 ± 1.0 |
| Reticulocytes, % | 3.5 ± 0.2*† | 36.8 ± 5.8 | 40.5 ± 4.7 | 16.4 ± 3.9*†§ | 14.7 ± 2.4*†§ | 38.5 ± 2.3 |
| WBC, × 103/μL | 7.1 ± 0.2*‡ | 14.4 ± 2.7 | 14.2 ± 3.5 | 6.9 ± 0.8*‡ | 10.0 ± 1.9 | 19.1 ± 4.2 |
| Neutrophils, % WBCs | 15.0 ± 2.8 | 13.1 ± 2.6 | 19.0 ± 3.4 | 12.1 ± 1.6 | 11.0 ± 1.6 | 33.9 ± 4.4*‡ |
| Lymphocytes, % WBCs | 78.3 ± 3.7 | 80.1 ± 3.7 | 76.3 ± 3.7 | 84.3 ± 1.8 | 87.5 ± 1.5 | 60.7 ± 4.5*†‡§ |
| Monocytes, % WBCs | 5.0 ± 1.4 | 7.1 ± 1.0†§ | 4.1 ± 0.4*† | 3.0 ± 0.5*† | 1.7 ± 0.3*†§ | 3.7 ± 1.1*‡ |
| Platelets, × 103/μL | 1023 ± 126*† | 523.3 ± 83 | 652.6 ± 166 | 430.4 ± 73 | 384.3 ± 24 | 612.0 ± 99 |
| RBC indices | ||||||
| MCV, fL | 52.2 ± 1.0 | 58.1 ± 1.9‡§ | 52.8 ± 1.8*‡ | 52.3 ± 1.6*‡ | 55.9 ± 1.8 | 57.7 ± 2.1 |
| MCH, pg | 15.4 ± 0.1‡§ | 14.9 ± 1.0 | 14.0 ± 0.6 | 13.5 ± 0.8 | 13.5 ± 0.7 | 14.1 ± 0.7 |
| MCHC, g/dL | 29.6 ± 0.7 | 25.9 ± 2.2 | 27.0 ± 1.8 | 24.8 ± 0.8 | 24.0 ± 0.5 | 24.3 ± 0.5 |
| Plasma | ||||||
| Free Hb, mg/dL | 26.6 ± 0.2*† | 82.4 ± 11.4 | 81.0 ± 11.3 | NT | NT | NT |
| Extramedullary organs | ||||||
| Spleen weight, % body weight | 0.34 ± 0.04*† | 4.1 ± 0.3*‡ | 4.9 ± 0.2*† | 2.8 ± 0.3*† | 2.0 ± 0.1*† | 4.1 ± 0.2‡§ |
| Parameter . | WT (C57BL/6) . | Vehicle . | Pomalidomide . | Hydroxyurea HD . | Pomalidomide + hydroxyurea (C/HD) . | Pomalidomide + hydroxyurea (C/LD) . |
|---|---|---|---|---|---|---|
| Peripheral blood | ||||||
| RBCs, × 106/μL | 8.9 ± 0.1*† | 4.8 ± 0.1 | 5.5 ± 0.2‡ | 4.5 ± 0.5 | 4.3 ± 0.4*‡ | 5.5 ± 0.2‡ |
| Total Hb, g/dL | 13.7 ± 0.2*† | 7.2 ± 0.4 | 7.7 ± 0.3 | 6.1 ± 0.5 | 5.7 ± 0.5*‡§ | 7.7 ± 0.3 |
| Hct, % | 46.6 ± 1.58*† | 28.2 ± 1.1 | 28.9 ± 1.2 | 23.6 ± 3.0 | 23.9 ± 2.0 | 31.7 ± 1.0 |
| Reticulocytes, % | 3.5 ± 0.2*† | 36.8 ± 5.8 | 40.5 ± 4.7 | 16.4 ± 3.9*†§ | 14.7 ± 2.4*†§ | 38.5 ± 2.3 |
| WBC, × 103/μL | 7.1 ± 0.2*‡ | 14.4 ± 2.7 | 14.2 ± 3.5 | 6.9 ± 0.8*‡ | 10.0 ± 1.9 | 19.1 ± 4.2 |
| Neutrophils, % WBCs | 15.0 ± 2.8 | 13.1 ± 2.6 | 19.0 ± 3.4 | 12.1 ± 1.6 | 11.0 ± 1.6 | 33.9 ± 4.4*‡ |
| Lymphocytes, % WBCs | 78.3 ± 3.7 | 80.1 ± 3.7 | 76.3 ± 3.7 | 84.3 ± 1.8 | 87.5 ± 1.5 | 60.7 ± 4.5*†‡§ |
| Monocytes, % WBCs | 5.0 ± 1.4 | 7.1 ± 1.0†§ | 4.1 ± 0.4*† | 3.0 ± 0.5*† | 1.7 ± 0.3*†§ | 3.7 ± 1.1*‡ |
| Platelets, × 103/μL | 1023 ± 126*† | 523.3 ± 83 | 652.6 ± 166 | 430.4 ± 73 | 384.3 ± 24 | 612.0 ± 99 |
| RBC indices | ||||||
| MCV, fL | 52.2 ± 1.0 | 58.1 ± 1.9‡§ | 52.8 ± 1.8*‡ | 52.3 ± 1.6*‡ | 55.9 ± 1.8 | 57.7 ± 2.1 |
| MCH, pg | 15.4 ± 0.1‡§ | 14.9 ± 1.0 | 14.0 ± 0.6 | 13.5 ± 0.8 | 13.5 ± 0.7 | 14.1 ± 0.7 |
| MCHC, g/dL | 29.6 ± 0.7 | 25.9 ± 2.2 | 27.0 ± 1.8 | 24.8 ± 0.8 | 24.0 ± 0.5 | 24.3 ± 0.5 |
| Plasma | ||||||
| Free Hb, mg/dL | 26.6 ± 0.2*† | 82.4 ± 11.4 | 81.0 ± 11.3 | NT | NT | NT |
| Extramedullary organs | ||||||
| Spleen weight, % body weight | 0.34 ± 0.04*† | 4.1 ± 0.3*‡ | 4.9 ± 0.2*† | 2.8 ± 0.3*† | 2.0 ± 0.1*† | 4.1 ± 0.2‡§ |
Data are mean ± SEM. Complete blood counts were measured from whole blood of 14-week-old mice after treatment with the indicated agent(s).
Hb indicates hemoglobin; Hct, hematocrit; WBC, white blood cell count; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; C/HD, combination high-dose treatment (10 mg/kg pomalidomide, 100 mg/kg hydroxyurea); C/LD, combination low-dose treatment (10 mg/kg pomalidomide, 10 mg/kg hydroxyurea); and NT, not tested.
Versus vehicle.
P < .01.
P < .05.
Versus pomalidomide.